Physician profile
Robert N Brems
NPI 1205926623
$2,976.37
in general payments reported to CMS, 2019-2025
28 companies · $553 in 2025
The $553 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $298 · 2021: $290 · 2022: $876 · 2023: $236 · 2024: $403 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,167 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,166.77 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $416.16 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Notal Vision, INC. | $304.73 | 2022 | |
| Abbvie INC. | $294.93 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $239.66 | 2019-2021 | |
| Rxsight INC | $216.42 | 2021-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Lensar, INC. | $160.75 | 2022 | |
| Sun Pharmaceutical Industries INC. | $148.90 | 2019-2025 | Cequa, Xelpros, Bromsite |
| Dompe US, INC. | $138.99 | 2019-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $124.58 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $121.44 | 2025 | Idosetr |
| Allergan, INC. | $111.10 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $103.70 | 2019-2022 | |
| Amgen INC. | $87.37 | 2024-2025 | Tepezza |
| Eyevance Pharmaceuticals LLC | $85.55 | 2020-2021 | |
| Alcon Vision LLC | $74.99 | 2022-2025 | Rocklatan, Tryptyr |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $46.28 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $44.69 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $41.64 | 2019 | |
| Harrow Eye, LLC | $38.94 | 2025 | Vevye |
| Apellis Pharmaceuticals, INC. | $30.02 | 2025 | Syfovre |
| Thea Pharma INC. | $27.71 | 2022-2024 | Iyuzeh |
| Sight Sciences, INC. | $22.82 | 2022 | |
| Mallinckrodt Hospital Products INC. | $21.64 | 2020 | |
| Akorn Operating Company LLC | $16.66 | 2021 | |
| Ocular Therapeutix, INC. | $14.43 | 2020 | |
| Mallinckrodt Enterprises LLC | $14.43 | 2019 | |
| Horizon Therapeutics Plc | $14.08 | 2021 | |
| Oyster Point Pharma, INC. | $13.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Brems listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.